Onderneming RXi Pharmaceuticals Corp Nasdaq
Aandelen
US74979C3034
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- USD | - |
Vakgebied
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 19-06-12 |
Caitlin Kontulis
DFI | Director of Finance/CFO | - | - |
James Cardia
CTO | Chief Tech/Sci/R&D Officer | - | 15-09-17 |
Linda M. Mahoney
PRN | Corporate Officer/Principal | - | 10-11-22 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 19-06-12 |
Director/Board Member | 73 | 02-05-22 | |
Curtis Lockshin
BRD | Director/Board Member | 64 | 18-04-13 |
Jonathan Freeman
BRD | Director/Board Member | 56 | 07-06-17 |
Robert Ferrara
BRD | Director/Board Member | 73 | 01-10-19 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 4 591 700 | 4 564 638 ( 99,41 %) | 0 | 99,41 % |
Bedrijfsgegevens
Phio Pharmaceuticals Corp.
11 Apex Drive Suite 300A PMB 2006
01752, Marlborough
+508-767-3861
http://www.phiopharma.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,94% | 49,18 mld. | |
+1,22% | 42,11 mld. | |
+50,18% | 40,37 mld. | |
-5,26% | 28,85 mld. | |
+13,53% | 26,09 mld. | |
-22,29% | 18,71 mld. | |
+7,81% | 13,26 mld. | |
+31,93% | 12,32 mld. | |
+0,12% | 11,99 mld. |
- Beurs
- Aandelen
- Koers PHIO
- Koers
- Onderneming RXi Pharmaceuticals Corp